118 patents
Utility
Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith
16 Jan 24
Massimo Ammirante, Sogole Bahmanyar, Matthew D. Correa, Virginia Heather Sharron Grant, Joshua Hansen, Evan J. Horn, Timothy S. Kercher, Christopher Mayne, Mark A. Nagy, Rama Krishna Narla, Surendra Nayak, Stephen Norris, Patrick Papa, Veronique Plantevin-Krenitsky, John J. Sapienza, Brandon W. Whitefield, Shuichan Xu
Filed: 16 Aug 21
Utility
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
9 Jan 24
Provided herein is a crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate.
Jerry Lee Atwood
Filed: 1 Oct 20
Utility
T lymphocyte production methods and t lymphocytes produced thereby
5 Dec 23
Provided herein are methods of generating T cells, e.g., cytotoxic T lymphocytes starting from peripheral blood mononuclear cells without a separate step of generating and isolating antigen-presenting cells, and with a single round of antigen stimulation.
Bitao Liang, Xiaohua Lu, Wei Liu, Kathy E. Karasciewicz-Mendez, Christopher Wiwi, Kruti Shah
Filed: 29 Dec 16
Utility
Treatment of cardiovascular disease using ActRII ligand traps
14 Nov 23
Provided herein are methods of treating diseases associated with vascular calcification and/or cardiovascular disease in a subject by using the level of a biomarker, in particular, snail homolog 1 (Snai1), phosphosmad2, phosphosmad3, urinary protein, dickkopf homolog 1 (Dkk1), collagen type 1 alpha 1 (Col1a1), activin (e.g., free activin), runt-related transcription factor 2 (Runx2), alkaline phosphatase (Alp), bone-specific alkaline phosphatase (BSAP), C-terminal type 1 collagen telopeptide (CTX), osterix, Klotho, alpha-smooth muscle actin (alpha-SMA), myocardin (MYOCD), activin receptor type 2A (ActRIIA), axis inhibition protein 2 (Axin2), and/or smooth muscle protein 22-alpha (Sm22-alpha), as an indicator(s) of responsiveness of the subject to the treatment, efficacy of the treatment, or appropriate dosage for the treatment with an activin type II receptor signaling inhibitor.
Keith Hruska, Yifu Fang, William Smith, Nianhang Chen
Filed: 8 Oct 15
Utility
Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
7 Nov 23
Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized.
Stewart Abbot, Tianjian Li, Bitao Liang
Filed: 5 Mar 21
Utility
Anti-CD47 antibodies and uses thereof
17 Oct 23
Provided herein are compositions, methods and uses involving antibodies that specifically bind to human CD47.
Aaron Sato, Ryan Stafford, Junhao Yang
Filed: 29 Oct 20
Utility
Methods of synthesis of (1R,2R,5R)-5-amino-2-methyl-cyclohexanol hydrochloride and intermediates useful therein
10 Oct 23
Provided herein are methods and intermediates for making (1R, 2R, 5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
Terrence Joseph Connolly, Hon-Wah Man
Filed: 3 Nov 21
Utility
Pharmaceutical compositions comprising (s)-4-(4-(4- (((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrtle and methods of using the
10 Oct 23
Provided herein are pharmaceutical compositions (e.g., oral dosage formulations) comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, mixture of enantiomers, tautomer, isotopolog, or pharmaceutically acceptable salt thereof, and a carrier or diluent.
Anjali Agrawal, Ming J. Chen, Shyam Babu Karki, Prajwal Gunwanth Thool, Dora Visky, Ruimin Xie
Filed: 8 Jan 20
Utility
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
22 Aug 23
Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
Brian E. Cathers, Philip Chamberlain, Antonia Lopez-Girona, Gang Lu
Filed: 21 Jul 20
Utility
Methods for treating multiple myeloma and the use of companion biomarkers for 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile
15 Aug 23
A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
Maria Soraya Carrancio Anton, Joshua Hansen, Courtney G. Havens, Antonia Lopez-Girona, Gang Lu, Lilly L. Wong
Filed: 10 Feb 21
Utility
Compositions and methods of use of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1- methylcyclohexane-1-carboxamide
18 Jul 23
Provided are formulations and dosage forms of cis-4-[2-{[(3S,4R)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl]-1-methylcyclohexane-1-carboxamide, alternatively named (1s,4s)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide, or a pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
Scott Bone, Tracy Lee Gaebele, Yu Pu, Lianfeng Huang
Filed: 22 Dec 20
Utility
3-(4-((4-(morpholinomethyl-benzyl)oxy)-1 -oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
30 May 23
Provided herein are methods of using compounds and compositions for treating, managing, and/or preventing systemic lupus erythematosus (SLE).
Peter H. Schafer, Lei Wu, Ying Ye
Filed: 29 Mar 21
Utility
Antiproliferative compounds and second active agents for combined use
30 May 23
Provided herein are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof, in combination with a second active agent for treating, preventing or managing multiple myeloma.
Lilly L. Wong
Filed: 8 Jan 20
Utility
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
23 May 23
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed.
Markian S. Jaworsky, Roger Shen-Chu Chen, George W. Muller
Filed: 2 Sep 21
Utility
Methods for measuring small molecule affinity to cereblon
9 May 23
A complex comprises a CRBN having a europium-anti-his antibody on the N-terminus of the CRBN, and a Cy5-conjugated small molecule, wherein the Cy5-conjugated small molecule binds the CRBN, and uses thereof for identifying therapeutic compounds.
Philip Paul Chamberlain, Mary Matyskiela, Godrej Khambatta
Filed: 18 Sep 20
Utility
Cereblon binding compounds, compositions thereof, and methods of treatment therewith
25 Apr 23
Matthew D. Alexander, Matthew D. Correa, Deepak Dalvie, Virginia Heather Sharron Grant, Joshua Hansen, Roy L. Harris, III, Evan J. Horn, Dehua Huang, Christopher Mayne, Stephen Norris, Veronique Plantevin-Krenitsky, John J. Sapienza, Lida Tehrani, Brandon W. Whitefield
Filed: 23 Jun 21
Utility
Methods of treating chronic lymphocytic leukemia using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
18 Apr 23
Provided herein are methods of using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, alone or in combination with obinutuzumab, for treating, preventing or managing chronic lymphocytic leukemia/small lymphocytic lymphoma.
Preethi Janardhanan, Shailaja Kasibhatla, Antonia Lopez-Girona, Michael Pourdehnad
Filed: 20 Oct 20
Utility
Methods of improving vector transduction efficiency into T lymphocytes
18 Apr 23
Provided herein are methods for enhancing the transduction efficiency of vectors into cells, e.g., primary human T lymphocytes.
Bitao Liang, Wei Liu
Filed: 12 Mar 21
Utility
Digital health prognostic analyzer for multiple myeloma mortality predictions
11 Apr 23
Computer-implemented systems and methods are provided for constructing a numerical model to generate a probability that a patient diagnosed with multiple myeloma will die within a predetermined period of time.
Shankar Swamimalai Srinivasan, Albert Elion-Mboussa
Filed: 30 Oct 17
Utility
Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
28 Feb 23
Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
Soraya Carrancio, Paul Hollenbach, Antonia Lopez-Girona, Kyle MacBeth, Michael Pourdehnad, Irit Rappley, Gang Lu
Filed: 2 Jul 20